KR100540720B1 - 신규형의 ｓ-오메프라졸 - Google Patents

신규형의 ｓ-오메프라졸 Download PDF

Info

Publication number
KR100540720B1
KR100540720B1 KR1019997011106A KR19997011106A KR100540720B1 KR 100540720 B1 KR100540720 B1 KR 100540720B1 KR 1019997011106 A KR1019997011106 A KR 1019997011106A KR 19997011106 A KR19997011106 A KR 19997011106A KR 100540720 B1 KR100540720 B1 KR 100540720B1
Authority
KR
South Korea
Prior art keywords
omeprazole
magnesium salt
magnesium
salt
trihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019997011106A
Other languages
English (en)
Korean (ko)
Other versions
KR20010013126A (ko
Inventor
한나 코튼
안더즈 크론스트룀
안더즈 마트슨
에바 묄러
Original Assignee
아스트라제네카 악티에볼라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100540720(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 악티에볼라그 filed Critical 아스트라제네카 악티에볼라그
Priority to KR10-2005-7006896A priority Critical patent/KR100527804B1/ko
Publication of KR20010013126A publication Critical patent/KR20010013126A/ko
Application granted granted Critical
Publication of KR100540720B1 publication Critical patent/KR100540720B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
KR1019997011106A 1997-05-30 1998-05-25 신규형의 ｓ-오메프라졸 Expired - Lifetime KR100540720B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2005-7006896A KR100527804B1 (ko) 1997-05-30 1998-05-25 Ｓ-오메프라졸의 칼륨염

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702065-5 1997-05-30
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening
PCT/SE1998/000974 WO1998054171A1 (en) 1997-05-30 1998-05-25 Novel form of s-omeprazole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR10-2005-7006896A Division KR100527804B1 (ko) 1997-05-30 1998-05-25 Ｓ-오메프라졸의 칼륨염

Publications (2)

Publication Number Publication Date
KR20010013126A KR20010013126A (ko) 2001-02-26
KR100540720B1 true KR100540720B1 (ko) 2006-01-12

Family

ID=20407186

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019997011106A Expired - Lifetime KR100540720B1 (ko) 1997-05-30 1998-05-25 신규형의 ｓ-오메프라졸
KR10-2005-7006896A Expired - Lifetime KR100527804B1 (ko) 1997-05-30 1998-05-25 Ｓ-오메프라졸의 칼륨염

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2005-7006896A Expired - Lifetime KR100527804B1 (ko) 1997-05-30 1998-05-25 Ｓ-오메프라졸의 칼륨염

Country Status (43)

Country Link
US (6) US6369085B1 (enExample)
EP (2) EP1273581B1 (enExample)
JP (2) JP4002303B2 (enExample)
KR (2) KR100540720B1 (enExample)
CN (1) CN1161351C (enExample)
AR (2) AR012717A1 (enExample)
AT (2) ATE239011T1 (enExample)
AU (1) AU722839B2 (enExample)
BR (1) BR9809509A (enExample)
CA (2) CA2290963C (enExample)
CY (1) CY2012029I2 (enExample)
CZ (1) CZ297585B6 (enExample)
DE (3) DE69829511T2 (enExample)
DK (2) DK0984957T3 (enExample)
DZ (1) DZ2495A1 (enExample)
EE (1) EE03875B1 (enExample)
EG (1) EG24291A (enExample)
ES (2) ES2195345T7 (enExample)
HR (1) HRP980263B1 (enExample)
HU (1) HU225987B1 (enExample)
ID (1) ID29306A (enExample)
IL (1) IL132947A0 (enExample)
IS (2) IS2142B (enExample)
LU (2) LU91871I2 (enExample)
MA (1) MA26500A1 (enExample)
ME (3) MEP24908A (enExample)
MY (2) MY120745A (enExample)
NO (3) NO317518B1 (enExample)
NZ (1) NZ500991A (enExample)
PL (1) PL193546B1 (enExample)
PT (2) PT984957E (enExample)
RS (2) RS50067B (enExample)
RU (1) RU2184115C2 (enExample)
SA (2) SA98190280B1 (enExample)
SE (1) SE510650C2 (enExample)
SI (2) SI1273581T1 (enExample)
SK (2) SK284837B6 (enExample)
TN (1) TNSN98074A1 (enExample)
TR (1) TR199902934T2 (enExample)
TW (1) TW538040B (enExample)
UA (1) UA60334C2 (enExample)
WO (1) WO1998054171A1 (enExample)
ZA (1) ZA984179B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60314105T2 (de) * 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
EP1515963B1 (en) * 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
CN100378093C (zh) * 2002-06-27 2008-04-02 雷迪实验室有限公司 一种制备包括无定形艾美拉唑及其盐在内的光学纯或光学浓缩的亚砜化合物的方法
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003262992A1 (en) * 2002-08-30 2004-03-19 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
EP2596792A1 (en) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2003278406A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
WO2004060263A2 (en) * 2003-01-07 2004-07-22 Ranbaxy Laboratories Limited Magnesium salt of imidazole derivative
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
US20070060556A1 (en) 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060189590A1 (en) * 2003-07-23 2006-08-24 Bernhard Kohl Alkaline salts of proton pump inhibitors
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
CA2556756A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
JP5457632B2 (ja) * 2004-06-24 2014-04-02 アストラゼネカ・アクチエボラーグ エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
EP1885711A1 (en) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
US7563812B2 (en) * 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
WO2007008588A2 (en) * 2005-07-07 2007-01-18 Dr. Reddy's Laboratories Ltd. Omeprazole form b
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
AU2006306906B2 (en) * 2005-10-26 2010-02-04 Hanmi Science Co., Ltd. S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
EP2040710A2 (en) * 2006-06-21 2009-04-01 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
KR101522865B1 (ko) * 2007-02-21 2015-05-26 시플라 리미티드 에소메프라졸 마그네슘 2수화물의 형태 a의 제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2008149204A1 (en) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
WO2009049160A1 (en) 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
WO2009099933A2 (en) * 2008-02-01 2009-08-13 Dr. Reddy's Laboratories Ltd. Preparation of esomeprazole magnesium and hydrates thereof
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2438057A4 (en) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd PROCESS FOR PREPARING SULFOXIDE COMPOUNDS
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
SG181535A1 (en) 2009-12-08 2012-07-30 Codexis Inc Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
WO2012078800A2 (en) 2010-12-08 2012-06-14 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102924435B (zh) * 2011-11-25 2014-06-25 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
EP3842575A4 (en) * 2018-08-21 2022-06-01 Towa Pharmaceutical Co., Ltd. SPECIFIC SHAPED CRYSTAL OF A COMPOUND AND METHOD OF PRODUCTION THEREOF
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification
CN119320380B (zh) * 2024-10-14 2025-11-25 山东益康药业股份有限公司 奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途
CN119320381B (zh) * 2024-10-14 2025-12-12 山东益康药业股份有限公司 奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124495A2 (en) * 1983-03-04 1984-11-07 Aktiebolaget Hässle Omeprazole salts

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US5244891A (en) * 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
MX9600857A (es) 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
ATE199375T1 (de) * 1994-11-14 2001-03-15 Daiichi Seiyaku Co Verfahren zur herstellung von 3-(2-(4-(3-chlor-2- methylphenyl)-1- piperazinyl) ethyl)-5,6- dimethoxy-1-(4-imidazolylmethyl)-1h-indazol- dihydrochlorid-3.5-hydrat.
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US6747155B2 (en) * 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124495A2 (en) * 1983-03-04 1984-11-07 Aktiebolaget Hässle Omeprazole salts

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제

Also Published As

Publication number Publication date
CA2521391C (en) 2009-09-29
EG24291A (en) 2009-01-08
DK1273581T3 (da) 2005-06-06
AR012717A1 (es) 2000-11-08
ID29306A (id) 2001-08-16
SA98190280B1 (ar) 2006-07-04
IL132947A0 (en) 2001-03-19
SI0984957T1 (en) 2003-10-31
PT984957E (pt) 2003-07-31
SA05260296B1 (ar) 2008-04-16
CY2012029I1 (el) 2015-08-05
RS50067B (sr) 2009-01-22
PT1273581E (pt) 2005-06-30
PL337180A1 (en) 2000-08-14
IS5272A (is) 1999-11-25
HUP0001849A3 (en) 2003-02-28
JP2002501529A (ja) 2002-01-15
AR059589A2 (es) 2008-04-16
SE510650C2 (sv) 1999-06-14
AU7793598A (en) 1998-12-30
TNSN98074A1 (fr) 2005-03-15
SK284837B6 (sk) 2005-12-01
CY2012029I2 (el) 2015-08-05
HRP980263B1 (en) 2002-02-28
MEP24908A (en) 2010-10-10
IS2142B (is) 2006-09-15
NO995852L (no) 2000-01-31
NO2011010I1 (no) 2011-06-20
ZA984179B (en) 1998-11-30
BR9809509A (pt) 2000-06-20
MY120745A (en) 2005-11-30
CN1161351C (zh) 2004-08-11
CA2290963A1 (en) 1998-12-03
NZ500991A (en) 2001-05-25
SE9702065D0 (sv) 1997-05-30
RS20070459A (sr) 2008-06-05
KR20010013126A (ko) 2001-02-26
MY127793A (en) 2006-12-29
EP0984957B3 (en) 2013-09-18
WO1998054171A8 (en) 1999-12-23
ES2236407T3 (es) 2005-07-16
US20120252847A1 (en) 2012-10-04
UA60334C2 (uk) 2003-10-15
US20110130570A1 (en) 2011-06-02
JP4002303B2 (ja) 2007-10-31
WO1998054171A1 (en) 1998-12-03
KR20050042827A (ko) 2005-05-10
EP1273581A1 (en) 2003-01-08
ME00198B (me) 2011-02-10
EP0984957A1 (en) 2000-03-15
DE69814069T3 (de) 2014-03-27
HK1025962A1 (en) 2000-12-01
SK162599A3 (en) 2000-06-12
US7745466B2 (en) 2010-06-29
DE69829511T2 (de) 2006-02-16
NO2012011I1 (no) 2012-06-18
ATE291574T1 (de) 2005-04-15
CA2290963C (en) 2006-03-28
EP0984957B1 (en) 2003-05-02
DZ2495A1 (fr) 2003-01-25
MA26500A1 (fr) 2004-12-20
AU722839B2 (en) 2000-08-10
JP2007161734A (ja) 2007-06-28
PL193546B1 (pl) 2007-02-28
US8076361B2 (en) 2011-12-13
ATE239011T1 (de) 2003-05-15
DK0984957T3 (da) 2003-06-30
DE69829511D1 (de) 2005-04-28
US8466175B2 (en) 2013-06-18
NO995852D0 (no) 1999-11-29
TW538040B (en) 2003-06-21
EP1273581B1 (en) 2005-03-23
SI1273581T1 (enExample) 2005-08-31
SK285137B6 (sk) 2006-07-07
IS8368A (is) 2006-03-22
KR100527804B1 (ko) 2005-11-15
DE69814069T2 (de) 2004-04-01
RU2184115C2 (ru) 2002-06-27
TR199902934T2 (xx) 2000-04-21
LU91871I2 (fr) 2011-11-21
YU60999A (sh) 2002-03-18
EE03875B1 (et) 2002-10-15
US7411070B2 (en) 2008-08-12
US20050075369A1 (en) 2005-04-07
LU92017I2 (fr) 2012-08-06
HU225987B1 (en) 2008-02-28
HU0001849D0 (enExample) 2002-05-29
CZ297585B6 (cs) 2007-01-10
NO317518B1 (no) 2004-11-08
MEP18008A (en) 2010-10-10
US6677455B2 (en) 2004-01-13
HK1051681A1 (en) 2003-08-15
IS2774B (is) 2012-03-15
ES2195345T7 (es) 2014-01-15
SE9702065L (sv) 1998-12-01
RS50005B (sr) 2008-09-29
DE122012000017I1 (de) 2012-08-16
US6369085B1 (en) 2002-04-09
US20020198239A1 (en) 2002-12-26
HRP980263A2 (en) 1999-02-28
EE9900550A (et) 2000-06-15
ES2195345T3 (es) 2003-12-01
CA2521391A1 (en) 1998-12-03
DE69814069D1 (de) 2003-06-05
CN1258295A (zh) 2000-06-28
US20080255363A1 (en) 2008-10-16
HUP0001849A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
KR100540720B1 (ko) 신규형의 ｓ-오메프라졸
KR100624054B1 (ko) (ｓ)-오메프라졸의 칼륨염
US6747155B2 (en) Process
HK1051681B (en) New process for the preparation of the trihydrate of the magnesium salt of s-omeprazole
HK1025962B (en) Novel form of s-omeprazole
CZ296154B6 (cs) Trihydrát horecnaté soli S-omeprazolu, zpusob jeho prípravy a farmaceutický prostredek s jeho obsahem
MXPA99010945A (en) Novel form of s
MXPA01007516A (en) Potassium salt of (s

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19991129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050222

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20050421

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050804

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20051111

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051227

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051228

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081014

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091016

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101129

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111129

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121130

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121130

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131129

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141201

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141201

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20151201

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20151201

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20161129

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20161129

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20181125

Termination category: Expiration of duration